Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomized, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee, PhD; Prof Kathleen N Moore, MD; Prof Nicoletta Colombo, PhD; Prof Giovanni Scambia, MD; Prof Byoung-Gie Kim, MD; Prof Ana Oaknin, MD; Prof Michael Friedlander, MD; Alla Lisyanskaya, MD; Anne Floquet, MD; Alexandra Leary, MD; Prof Gabe S Sonke, MD; Prof Charlie Gourley, PhD; Prof Amit Oza, MD; Antonio González-Martín, MD; Prof Carol Aghajanian, MD;
William H Bradley, MD; Eileen Holmes, PhD; Elizabeth S Lowe, MD; Prof Paul DiSilvestro, MD

The Lancet Oncology, October 26, 2021

Link all’abstract